TABLE OF CONTENTS
1 INTRODUCTION 53
1.1 OBJECTIVES OF THE STUDY 53
1.2 MARKET DEFINITION 53
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET 53
1.4 LIMITATIONS 55
1.5 MARKETS COVERED 55
2 MARKET SEGMENTATION 58
2.1 MARKETS COVERED 58
2.2 GEOGRAPHICAL SCOPE 59
2.3 YEARS CONSIDERED FOR THE STUDY 60
2.4 CURRENCY AND PRICING 60
2.5 DBMR TRIPOD DATA VALIDATION MODEL 61
2.6 MULTIVARIATE MODELLING 64
2.7 PRODUCT LIFELINE CURVE 65
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
2.9 DBMR MARKET POSITION GRID 67
2.10 MARKET APPLICATION COVERAGE GRID 69
2.11 VENDOR SHARE ANALYSIS 70
2.12 SECONDARY SOURCES 71
2.13 ASSUMPTIONS 71
3 EXECUTIVE SUMMARY 72
4 PREMIUM INSIGHTS 74
4.1 PESTEL ANALYSIS 75
4.2 PORTER'S FIVE FORCES MODEL 76
4.3 SUPPLY CHAIN ANALYSIS 77
4.4 VALUE CHAIN ANALYSIS 78
4.5 BUSINESS STRATEGY EXCELLENCE 79
4.6 CASE STUDIES 80
4.7 STRENGTH OF PRODUCT PORTFOLIO 82
4.8 TECHNOLOGICAL TRENDS 84
4.9 PRICING ANALYSIS 85
5 INDUSTRY INSIGHTS 86
6 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET, REGULATIONS 87
7 MARKET OVERVIEW 89
7.1 DRIVERS 91
7.1.1 GROWING PREVALENCE OF CANCER, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE, LYME DISEASE, AND OTHER CHRONIC DEGENERATIVE DISEASES 91
7.1.2 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D AND LIFE SCIENCES RESEARCH 91
7.1.3 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES AND PROGRESSING THERAPEUTIC VALUE OF EXOSOME 92
7.2 RESTRAINTS 93
7.2.1 LACK OF GOLD STANDARD PROTOCOLS FOR THE DEVELOPMENT AND PRODUCTION OF EXOSOMES 93
7.2.2 THE SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE ISOLATION OF EXOSOME 93
7.3 OPPORTUNITIES 94
7.3.1 RISING DEMAND FOR SPECIALIZED TESTING SERVICES AMONG END USERS. 94
7.3.2 INCREASING ADVANCEMENT IN EXOSOME TECHNOLOGY 94
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 95
7.4 CHALLENGES 96
7.4.1 SIDE EFFECTS ASSOCIATED WITH EXOSOME RESEARCH PRODUCTS 96
7.4.2 LATE APPROVAL ASSOCIATED WITH PRODUCT LAUNCHES 96
8 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET, BY PRODUCT 97
8.1 OVERVIEW 98
8.2 CONSUMABLES 101
8.2.1 KITS AND REAGENTS 102
8.2.1.1 EXOSOME BIOMARKER KITS 103
8.2.1.2 EXOSOME ISOLATION KITS 103
8.2.1.3 EXOSOME PURIFICATION KITS 103
8.2.1.4 EXOSOME QUANTITATIVE KITS 103
8.2.1.5 EXOSOME DETECTION KITS 103
8.2.1.6 OTHERS 103
8.2.2 EXOSOME STANDARDS 103
8.2.3 EXOSOME ANTIBODIES 103
8.2.4 CELL LINES 103
8.2.5 IMMUNOPLATES 104
8.2.6 IMMUNOBEADS 104
8.2.7 BIOFLUIDS 104
8.2.8 OTHERS 104
8.3 INSTRUMENTS 104
8.3.1 BENCHTOP 105
8.3.2 STANDALONE 105
9 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET, BY INDICATION 106
9.1 OVERVIEW 107
9.2 CANCER 110
9.2.1 LUNG CANCER 111
9.2.2 BREAST CANCER 111
9.2.3 COLORECTAL CANCER 111
9.2.4 PROSTATE CANCER 112
9.2.5 OTHER CANCER 112
9.3 NON-CANCER 112
9.3.1 CARDIOVASCULAR DISEASE 113
9.3.2 NEURODEGENERATIVE DISEASE 113
9.3.3 INFECTIOUS DISEASE 113
9.3.4 OTHERS 113
10 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET: BY APPLICATION 114
10.1 OVERVIEW 115
10.2 THERAPEUTICS 118
10.3 CONSUMABLES 119
10.4 INSTRUMENTS 119
10.5 DIAGNOSIS 119
10.6 CONSUMABLES 120
10.7 INSTRUMENTS 120
11 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET, BY END USER 121
11.1 OVERVIEW 122
11.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANY 125
11.3 CONSUMABLES 126
11.4 INSTRUMENTS 126
11.5 RESEARCH CENTRES 126
11.6 CONSUMABLES 127
11.7 INSTRUMENTS 127
11.8 ACADEMIC INSTITUTES 127
11.9 CONSUMABLES 128
11.10 INSTRUMENTS 128
11.11 CLINICAL TESTING LABORATORY 128
11.12 CONSUMABLES 129
11.13 INSTRUMENTS 129
11.14 HOSPITALS 130
11.15 CONSUMABLES 131
11.16 INSTRUMENTS 131
11.17 OTHERS 131
12 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 132
12.1 OVERVIEW 133
12.2 THIRD PARTY DISTRIBUTORS 136
12.3 DIRECT SALES 136
12.4 ONLINE 137
13 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET, BY REGION 138
13.1 MIDDLE EAST AND AFRICA 139
13.1.1 SOUTH AFRICA 149
13.1.2 EGYPT 155
13.1.3 SAUDI ARABIA 161
13.1.4 U.A.E 167
13.1.5 BAHARAIN 172
13.1.6 KUWAIT 178
13.1.7 OMAN 184
13.1.8 QATAR 190
13.1.9 MIDDLE EAST AND AFRICA 196
14 MIDDLE EAST & AFRICA EXOSOME RESEARCH PRODUCTS MARKET, COMPANY LANDSCAPE 197
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 197
15 SWOT ANALYSIS 198
16 COMPANY PROFILE 199
16.1 THERMO FISHER SCIENTIFIC INC. 199
16.1.1 COMPANY SNAPSHOT 199
16.1.2 REVENUE ANALYSIS 199
16.1.3 COMPANY SHARE ANALYSIS 200
16.1.4 PRODUCT PORTFOLIO 200
16.1.5 RECENT DEVELOPMENT 201
16.2 EXODX (ACQUIRED BY BIO-TECHNE) 202
16.2.1 COMPANY SNAPSHOT 202
16.2.2 REVENUE ANALYSIS 202
16.2.3 COMPANY SHARE ANALYSIS 203
16.2.4 PRODUCT PORTFOLIO 203
16.2.5 RECENT DEVELOPMENT 203
16.3 MILTENYI BIOTEC 204
16.3.1 COMPANY SNAPSHOT 204
16.3.2 COMPANY SHARE ANALYSIS 204
16.3.3 PRODUCT PORTFOLIO 205
16.3.4 RECENT DEVELOPMENTS 205
16.4 LUMINEX CORPORATION 206
16.4.1 COMPANY SNAPSHOT 206
16.4.2 PRODUCT PORTFOLIO 206
16.4.3 RECENT DEVELOPMENT 206
16.5 HOLOGIC, INC. 207
16.5.1 COMPANY SNAPSHOT 207
16.5.2 REVENUE ANALYSIS 207
16.5.3 COMPANY SHARE ANALYSIS 208
16.5.4 PRODUCT PORTFOLIO 208
16.5.5 RECENT DEVELOPMENTS 208
16.6 AETHLON MEDICAL, INC. (2022) 209
16.6.1 COMPANY SNAPSHOT 209
16.6.2 PRODUCT PORTFOLIO 210
16.6.3 RECENT DEVELOPMENTS 210
16.7 AGILENT TECHNOLOGIES, INC. 211
16.7.1 COMPANY SNAPSHOT 211
16.7.2 REVENUE ANALYSIS 211
16.7.3 PRODUCT PORTFOLIO 212
16.7.4 RECENT DEVELOPMENT 212
16.8 AMSBI0 213
16.8.1 COMPANY SNAPSHOT 213
16.8.2 PRODUCT PORTFOLIO 213
16.8.3 RECENT DEVELOPMENT 213
16.9 AUDUBON BIOSCIENCE. 214
16.9.1 COMPANY SNAPSHOT 214
16.9.2 PRODUCT PORTFOLIO 214
16.9.3 RECENT DEVELOPMENT 214
16.10 BECKMAN COULTER, INC 215
16.10.1 COMPANY SNAPSHOT 215
16.10.2 PRODUCT PORTFOLIO 215
16.10.3 RECENT DEVELOPMENT 215
16.11 BIOVISION INC. (ACQUIRED BY ABCAM PLC) 216
16.11.1 COMPANY SNAPSHOT 216
16.11.2 REVENUE ANALYSIS 216
16.11.3 COMPANY SHARE ANALYSIS 217
16.11.4 PRODUCT PORTFOLIO 217
16.11.5 RECENT DEVELOPMENT 217
16.12 CELL GUIDANCE SYSTEMS LLC 218
16.12.1 COMPANY SNAPSHOT 218
16.12.2 PRODUCT PORTFOLIO 218
16.12.3 RECENT DEVELOPMENTS 218
16.13 CREATIVE BIOARRAY 219
16.13.1 COMPANY SNAPSHOT 219
16.13.2 PRODUCT PORTFOLIO 219
16.13.3 RECENT DEVELOPMENT 219
16.14 CUSABIO TECHNOLOGY LLC 220
16.14.1 COMPANY SNAPSHOT 220
16.14.2 PRODUCT PORTFOLIO 220
16.14.3 RECENT DEVELOPMENTS 220
16.15 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION 221
16.15.1 COMPANY SNAPSHOT 221
16.15.2 REVENUE ANALYSIS 221
16.15.3 PRODUCT PORTFOLIO 222
16.15.4 RECENT DEVELOPMENT 222
16.16 HBMLS (ACQUIRED BY LONZA) 223
16.16.1 COMPANY SNAPSHOT 223
16.16.2 REVENUE ANALYSIS 223
16.16.3 PRODUCT PORTFOLIO 224
16.16.4 RECENT DEVELOPMENT 224
16.17 HITACHI, LTD. 225
16.17.1 COMPANY SNAPSHOT 225
16.17.2 REVENUE ANALYSIS 225
16.17.3 PRODUCT PORTFOLIO 226
16.17.4 RECENT DEVELOPMENT 226
16.18 INOVIQ 227
16.18.1 COMPANY SNAPSHOT 227
16.18.2 REVENUE ANALYSIS 227
16.18.3 PRODUCT PORTFOLIO 228
16.18.4 RECENT DEVELOPMENT 228
16.19 JSR MICRO NV 229
16.19.1 COMPANY SNAPSHOT 229
16.19.2 PRODUCT PORTFOLIO 229
16.19.3 RECENT DEVELOPMENT 229
16.20 MICROGENTAS 230
16.20.1 COMPANY SNAPSHOT 230
16.20.2 PRODUCT PORTFOLIO 230
16.20.3 RECENT DEVELOPMENTS 230
16.21 NANOSOMIX 231
16.21.1 COMPANY SNAPSHOT 231
16.21.2 PRODUCT PORTFOLIO 231
16.21.3 RECENT DEVELOPMENT 231
16.22 NEXOSOME-ONCOLOGY 232
16.22.1 COMPANY SNAPSHOT 232
16.22.2 PRODUCT PORTFOLIO 232
16.22.3 RECENT DEVELOPMENTS 232
16.23 NORGEN BIOTEK CORP. 233
16.23.1 COMPANY SNAPSHOT 233
16.23.2 PRODUCT PORTFOLIO 233
16.23.3 RECENT DEVELOPMENTS 233
16.24 NOVUS BIOLOGICALS 234
16.24.1 COMPANY SNAPSHOT 234
16.24.2 PRODUCT PORTFOLIO 234
16.24.3 RECENT DEVELOPMENT 235

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.